Dean B. Evans
Novartis (Switzerland)(CH)Medical College of Wisconsin(US)Bioscientifica (United Kingdom)(GB)Novartis Institutes for BioMedical Research
Publications by Year
Research Areas
Estrogen and related hormone effects, Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Cytokine Signaling Pathways and Interactions, Bone Metabolism and Diseases
Most-Cited Works
- → Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial(2001)1,062 cited
- → Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics(2008)653 cited
- → In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase(2004)536 cited
- → Dual Inhibition of mTOR and Estrogen Receptor SignalingIn vitroInduces Cell Death in Models of Breast Cancer(2005)335 cited
- Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.(2003)
- → Intratumoral Estrogens and Estrogen Receptors in Human Non–Small Cell Lung Carcinoma(2008)193 cited